Mending a broken heart with biotech

French company CellProthera has seen some remarkable results treating people who have had a heart attack.  On this week’s podcast, the company’s CEO Matthieu de Kalbermatten tells us how it works.01:00-03:29: About CellProthera03:30-06:30: What are ProtheraCytes?06:30-09:02: Is this a cure?09:02-10:24: Is prevention the best option?10:25-11:49: Is this therapy useful to treat other conditions?11:50-13:55: How quickly do you need to treat a patient?13:56-16:39: The field of regenerative therapy16:39-17:52: Is regenerative therapy a growing sector?17:53-18:26: Clinical trials18:26-19:22: Upcoming phase 3 trials19:22-20:36: The regulatory pathway20:37-23:25: Cost and scale23:25-24:20: The need for partnerships24:21-24:57: Next steps24:57-28:30: Is there excitement in the medical field for this treatment?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter